A carregar...
FDA-Approved Biosimilar Insulin: Good Enough for Critical Care, Adulterated, or Counterfeit? How Can We Tell?
If a biosimilar insulin is discovered postmarketing to be subpotent, superpotent, or contaminated or the contents mislabeled, it is an adulterated product and must be quarantined for removal including from a patient’s home. Adulterated products could be considered “counterfeit” since they do not mee...
Na minha lista:
| Publicado no: | J Diabetes Sci Technol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4455370/ https://ncbi.nlm.nih.gov/pubmed/25172881 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296814539275 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|